HST Global Announces Launch of FocusUP Website

HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced the official launch of the FocusUP® Website located at www.focusup.com. FocusUP® is the cognitive function product endorsed and recommended by Dr. Kyl Smith under a Joint Venture with Dalham, LLC (an affiliate company of The Health Network, Inc.).

“We are pleased to announce the launch of our new FocusUP® website. With the introduction of the new website, we will have the ability to educate the public on the benefits of FocusUP ®, Dr. Kyl Smith’s cognitive function product. We encourage you to go to www.focusup.com to learn more.”

Ron Howell, CEO/President stated, “We are pleased to announce the launch of our new FocusUP® website. With the introduction of the new website, we will have the ability to educate the public on the benefits of FocusUP ®, Dr. Kyl Smith’s cognitive function product. We encourage you to go to www.focusup.com to learn more.”

Product and ordering information regarding FocusUP® can be found at www.focusup.com. You can also visit www.brightermind.com to find out more information about Dr. Kyl Smith.

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.